Never miss a profitable trade. (Add your “underperform” vote.). View which stocks have been most impacted by COVID-19. Akebia Therapeutics has received a consensus rating of Buy. Free Signup : Top 50 Stocks Top 10 Penny Stocks Bullish Engulfing Scanner … AKBA stock news . It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The P/E ratio of Akebia Therapeutics is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Sr. VP, Chief Accounting Officer & Principal Accounting Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month, Looking Into Akebia Therapeutics's Return On Capital Employed, Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference, Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2020 Results - Earnings Call Transcript, Why Akebia Therapeutics Stock Is Plunging Today, Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates, Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors, Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights, Return On Capital Employed Overview: Akebia Therapeutics, Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference, Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference, Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options, AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal. Akebia Therapeutics stock forecast, AKBA price prediction: Buy or sell Akebia Therapeutics, Inc. shares? Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke. Learn everything you need to know about successful options trading with this three-part video course. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The AKBA stock will be analyzed using Smart Scan and the Trade Triangle technology. 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last twelve months.

Lubricant Meaning In Telugu, Kim's Convenience Season 5 Cbc, Fotos De Chicas Para Perfil De Whatsapp, Mindvalley Be Extraordinary Review, Hack Etf Reddit,